中關村(000931.SZ):公司藥品入選2024年國家醫保目錄
格隆匯12月11日丨中關村(000931.SZ)公吿,其全資子公司四環醫藥控股的北京華素、山東華素及四環醫藥控股的多多藥業共有34個產品入選《醫保目錄2024年》。其中包括富馬酸比索洛爾片、鹽酸貝尼地平片、鹽酸羥考酮片、鹽酸納洛酮注射液等原進入2023年國家醫保目錄的產品。公司入選產品相較《醫保目錄2023年》無變化。入選目錄產品未來的銷售情況可能受到市場環境變化等多重因素影響,不會對公司當期經營業績產生重大影響。《醫保目錄2024年》將於2025年1月1日起正式實施。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.